We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

55 hedge funds and large institutions have $13.3M invested in Navidea Biopharmaceuticals Inc. in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $10.7M → $13.3M (+$2.55M)

13% less funds holding

Funds holding: 63 → 55 (-8)

53% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 15

57% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 14

91% less call options, than puts

Call options by funds: $10K | Put options by funds: $116K

Holders
55
Holders Change
-8
Holders Change %
-12.7%
% of All Funds
1.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
15
Closed
14
Calls
$10K
Puts
$116K
Net Calls
-$106K
Net Calls Change
-$77K

Top Buyers

Rank Fund Capital Flow
1
BIT
BlackRock Institutional Trust
California
+$924K
2
HIIFS
Harel Insurance Investments & Financial Services
Israel
+$190K
3
SIM
Spark Investment Management
New York
+$149K
4
Citadel Advisors
Citadel Advisors
Florida
+$34.7K
5
GC
Guggenheim Capital
Illinois
+$31.6K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$2.06M
2
PP
Paloma Partners
Connecticut
-$297K
3
Millennium Management
Millennium Management
New York
-$234K
4
LCM
Laurion Capital Management
New York
-$233K
5
CS
Credit Suisse
Switzerland
-$217K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
51
Alexandria Capital
Virginia
$1K – – –
Citigroup
52
Citigroup
New York
$1K – – –
Manulife (Manufacturers Life Insurance)
53
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1K – – –
CA
54
Commerzbank Aktiengesellschaft
Germany
– -$3.56K -335,203 Closed
PP
55
Paloma Partners
Connecticut
– -$297K -27,969 Closed
LCM
56
Laurion Capital Management
New York
– -$233K -21,920 Closed
CS
57
Credit Suisse
Switzerland
– -$217K -20,421 Closed
LP
58
LMR Partners
United Kingdom
– -$151K -14,179 Closed
OAM
59
Oxford Asset Management
United Kingdom
– -$141K -13,265 Closed
Stifel Financial
60
Stifel Financial
Missouri
– -$116K -10,898 Closed
AGM
61
Alpine Global Management
New York
– -$108K -10,158 Closed
ARTA
62
A.R.T. Advisors
New York
– -$104K -9,891 Closed
Squarepoint
63
Squarepoint
New York
– -$74K -6,930 Closed
Jacobs Levy Equity Management
64
Jacobs Levy Equity Management
New Jersey
– -$57K -5,385 Closed
VKH
65
Virtu KCG Holdings
New York
– -$47K -4,442 Closed
New York State Common Retirement Fund
66
New York State Common Retirement Fund
New York
– -$22K -2,060 Closed
TRCT
67
Tower Research Capital (TRC)
New York
– -$21K -1,953 Closed
JFA
68
JNBA Financial Advisors
Minnesota
– +$316 +25 New
S
69
SignatureFD
Georgia
– +$316 +25 New
1 2
3

NAVB Hedge Fund Activity: Q3 2016 in Review

55 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2016, worth a combined $13.3M — up 24% from $10.7M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of NAVB and 6 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 7 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $924K. The largest seller was Goldman Sachs, cutting an estimated $2.06M.

  • 55 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2016, down from 63 in Q2 2016.
  • Funds reported $13.3M of Navidea Biopharmaceuticals Inc. stock for Q3 2016, up 24% quarter-over-quarter.
  • 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2016 and 14 closed out, a net change of -8 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2016 was BlackRock Institutional Trust, an estimated $924K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q3 2016 was Goldman Sachs, an estimated $2.06M sold.

Based on aggregated 13F filings for Q3 2016.